Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of inflammation and autoimmune disease.

Researchers at Cerevance Inc. and Cerevance Ltd. have identified heterobicyclic amides acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of aging, diabetic nephropathy, glaucoma, inflammatory disorders, metabolic syndrome, obesity and rheumatoid arthritis, among others.

Haisco Pharmaceutical Group Co. Ltd. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

LG Chem Ltd. has disclosed diacylglycerol kinase α (DGK-α, DGKA) inhibitors reported to be useful for the treatment of cancer.

Nanjing Shijiang Medicine Technology Co. Ltd. has described phosphorus compounds reported to be useful for the treatment of cancer.

Korea Institute of Science and Technology has described nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators acting as nitric oxide (NO) production inhibitors and antioxidants reported to be useful for the treatment of acute respiratory distress syndrome, chronic kidney disease, chronic obstructive pulmonary disease, kidney fibrosis, nonalcoholic fatty liver disease, viral hepatitis, Parkinson’s disease and Alzheimer’s disease.

University of Minnesota has divulged nonstructural protein 14 (NSP14) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.

Researchers at Centre Hospitalier de Université de Montréal and University of Pennsylvania have identified compounds reported to be useful for the treatment of HIV-1 infection.

Xiamen University has synthesized oligopeptides targeting β2-microglobulin (B2M) reported to be useful for the treatment of cancer and Alzheimer’s disease.